This is in contrast with what has been found by others, e.g., co-administration of IMQ and anti-CD40 is ineffective against intradermal B16 melanomas, and required a combination of TLR3, TLR4 and TLR7 stimulation to produce 50% tumor rejection [25]. The gene discussed is TLR4; the disease is melanoma.